Molecular Partners AG has the GF Score of 27, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Molecular Partners AG
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Molecular Partners AG (XSWX:MOLN) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Molecular Partners AG GF Score Related Terms
XSWX:MOLN vs VRTX, REGN, ALNY: GF Score Comparison
For the Biotechnology subindustry, Molecular Partners AG's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's GF Score distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's GF Score falls into.
Molecular Partners AG (XSWX:MOLN) has a GF Score of 27 as of Jun. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Molecular Partners AG and its competitors. This is 34% below median its historical median of 41.00. Over the past decade, Molecular Partners AG's GF Score has ranged from 8.00 to 64.00.
Is Molecular Partners AG's GF Score too high?
Molecular Partners AG's current GF Score of 27 is 34% below median its 10-year median of 41.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 64.00. Overall, Molecular Partners AG has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's GF Score compare to VRTX and REGN?
Molecular Partners AG's GF Score of 27 can be compared against companies in the Biotechnology industry. Historically, Molecular Partners AG's own GF Score has ranged from 8.00 to 64.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current GF Score is 27, which is 34% below median its own 10-year median of 41.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.18 — trading 759.5% above its estimated fair value. The current GF Score is 27, which is 34% below median its 10-year median of 41.00. Molecular Partners AG's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current GF Score is 27 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of CHF3.18 is trading 759.5% above its estimated GF Value™ of CHF0.37.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for XSWX:MOLN:
GF Score: 27 (34% below median its 10-year median of 41.00)
GF Value™: CHF0.37 vs. price of CHF3.18 (759.5% above fair value)
No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
27GF Score
Get the complete analysis for XSWX:MOLN
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MOLN has been successfully added to your 